*Signing event on November 25, 2023 in Taipei, from left to right; ①Hirohiko Tsujii, Vice President, Association for Nuclear Technology in Medicine (Adviser in B dot Medical), ②Takuji Furukawa, B dot Medical’s CEO, ③Tsai Ming-hao, Quatherapy’s CEO, ④Jeng-Fong Chiou, President, Taiwan Society for Therapeutic Radiology and Oncology (TASTRO), and ⑤Hsin-Lun Lee, Secretary-General, Taiwan Society for Therapeutic Radiology and Oncology (TASTRO).
B dot Medical is a medical startup, aiming to make “PROTON for everyone” a reality by developing an ultra-compact, high-performance, and efficient proton therapy system. Historically, proton therapy adoption has been hindered by the size of traditional systems. However, B dot Medical has achieved a breakthrough with its proprietary “Magnetic Gantry™” using superconducting technologies, successfully reducing the height of the beam delivery device to approximately one-third of conventional systems, making it comparable to existing X-ray therapy equipment.
Meanwhile, Quatherapy Inc. is a company established specifically to support and promote B dot Medical’s proton therapy system in Taiwan. The company’s goal is to ensure the comprehensive implementation and application of B dot Medical’s proton therapy technology in Taiwan, bringing the best treatment solutions to local cancer patients. Quatherapy is responsible for all associated tasks from applying for medical device certification, sales, to installation and maintenance.
The agreement, inked between the two companies on November 25th in Taipei, underscores their mutual vision to make advanced proton therapy more accessible to the people of Taiwan. With 15 proton or heavy particle treatment centers either in operation, approved, or currently under application in Taiwan as of March 2023, the country is well on its way to becoming the most densely populated nation in the world for particle treatment. It’s worth noting that some of the approved facilities are yet to decide on their equipment provider. The strategic partnership aims to facilitate the orders for B dot Medical’s proton therapy systems in five of these approved facilities or potential new ones over the next several years.
Takuji Furukawa, B dot Medical’s President and CEO, commented, “this partnership is poised to accelerate improved access to proton therapy for the people of Taiwan, bringing newfound hope to both patients and medical professionals. B dot Medical’s revolutionary ultra-compact system, with its high performance and efficiency, promises to transform cancer treatment in the region. With our innovative technology, patients can experience cutting-edge care, while medical professionals gain access to a state-of-the-art tool that empowers their efforts to combat cancer effectively.”
“We are committed to bringing innovative proton therapy technology to Taiwanese healthcare professionals and patients through this collaboration, thereby enhancing the efficiency and effectiveness of cancer treatment”, Tsai Ming-hao, Quatherapy’s CEO, commented. ”We are pleased about our cooperation with B dot Medical. This partnership is not only strategically important for both companies but also represents a significant milestone in advancing cancer treatment technologies in Taiwan.”
